Core Insights - Jinbo Bio reported a significant increase in net profit for 2024, with a year-on-year growth of 144.27% [1] - The company's operating revenue reached 1.44 billion, marking an 84.92% increase compared to the previous year [1] - The gross profit margin improved to 92.02%, up by 1.86 percentage points from the previous year [2] Financial Performance - Operating revenue for 2024 was 1,442,831,399.69, compared to 780,260,212.25 in 2023, reflecting an 84.92% increase [1] - Net profit attributable to shareholders was 732,301,620.38, a 144.27% increase from 299,796,292.39 in 2023 [1] - The net profit after deducting non-recurring gains and losses was 712,180,480.92, up 149.15% from 285,842,673.17 in the previous year [1] - Basic earnings per share rose to 8.27, a 131.65% increase from 3.57 in 2023 [1] Cost and Expenses - Total period expenses for 2024 were 467 million, an increase of 114 million from the previous year [2] - The expense ratio decreased to 32.40%, down by 12.86 percentage points compared to the previous year [2] - Sales expenses increased by 56.73%, while management expenses rose by 38.08% [2] - Research and development expenses decreased by 16.20%, and financial expenses fell by 5.46% [2] Employee Statistics - The total number of employees increased to 823 in 2024, up from 730 in the previous year, representing a 13.29% growth [3] Leadership and Governance - The chairman of Jinbo Bio, Yang Xia, received a salary of 2.2 million in 2024, a decrease of 18.46% from 2.698 million in 2023 [4] - The company has a diverse leadership team with various educational backgrounds, including PhDs and master's degrees [3][5] Company Overview - Jinbo Bio, established on March 28, 2008, specializes in the research, production, and sales of medical devices and functional skincare products, focusing on recombinant collagen products and anti-HPV biological protein products [5]
锦波生物净利大增144%，女董事长杨霞年薪降两成、曾任8年大学讲师